Robert Balfour
Director at Axovia Therapeutics
Robert Balfour
Director at Axovia Therapeutics
Greater London, England
Overview
Work Experience
Director
2023 - Current
Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome.
Director
2023
Founding CEO
2021 - 2023
Promatix is a developing a new target discovery and validation platform to develop the next generation of cancer therapeutics
Board Observer
2019
Board Observer
2018
Investment Director
2018
ALSA Ventures is a Europe based biotechnology investment firm with a focus on novel therapeutics at preclinical POC or early clinical development stage. The firm is managed by the founder and ex-CEO of Novotech, a leading midsize clinical CRO. As such, we bring considerable expertise and experience to assets in clinical development, and are an active investor. We have no geographic or therapeutic area constraints, and are equally open to seeding new companies, as investing in later syndicated rounds, or as a sole investor.
Chief Business Officer
2018 - 2021
Viatem is a University of Birmingham Spinout company working to exploit the therapeutic potential of PEPITEM, a novel peptide, discovered by Prof. Ed Rainger. PEPITEM controls inflammation by regulating T-Cell migration and is compromised in a range of important chronic inflammatory diseases
Partner & Co-founder
2017 - 2019
Board Observer
2016 - 2017
Investment Manager
2015 - 2017
Nestlé’s strategic healthcare-focused venture capital fund covering diagnostics, devices, OTC, nutraceuticals and pharmaceuticals.
Board Observer
2015 - 2017